{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:44:09Z","timestamp":1783950249417,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T00:00:00Z","timestamp":1508371200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s00280-017-3462-y","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T01:36:31Z","timestamp":1508376991000},"page":"1055-1062","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea"],"prefix":"10.1007","volume":"80","author":[{"given":"Muhammad","family":"Masab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Wasif","family":"Saif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,19]]},"reference":[{"issue":"Suppl 1","key":"3462_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000080731","volume":"80","author":"BG Taal","year":"2004","unstructured":"Taal BG, Visser O (2004) Epidemiology of neuroendocrine tumours. Neuroendocrinology 80(Suppl 1):3\u20137","journal-title":"Neuroendocrinology"},{"issue":"7","key":"3462_CR2","doi-asserted-by":"publisher","first-page":"902","DOI":"10.2174\/1871520617666170213113401","volume":"17","author":"I Legakis","year":"2017","unstructured":"Legakis I, Saif MW, Syrigos K (2017) Therapeutic challenges in neuroendocrine tumors. Anticancer Agents Med Chem 17(7):902\u2013919. doi: 10.2174\/1871520617666170213113401","journal-title":"Anticancer Agents Med Chem"},{"key":"3462_CR3","doi-asserted-by":"crossref","unstructured":"Kulke MH, Mayer RJ (1999) Carcinoid tumors. N Engl J Med 340:858\u2013868","DOI":"10.1056\/NEJM199903183401107"},{"key":"3462_CR4","doi-asserted-by":"crossref","unstructured":"Mocellin S, Nitti D (2013) Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol mdt377","DOI":"10.1093\/annonc\/mdt377"},{"issue":"3","key":"3462_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1517\/14656566.2016.1127914","volume":"17","author":"MW Saif","year":"2016","unstructured":"Saif MW (2016) Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Opin Pharmacother 17(3):443\u201356. doi: 10.1517\/14656566.2016.1127914","journal-title":"Expert Opin Pharmacother"},{"key":"3462_CR6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","volume":"41","author":"JL Beaumont","year":"2012","unstructured":"Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC (2012) Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas 41:461\u2013466","journal-title":"Pancreas"},{"issue":"117","key":"3462_CR7","first-page":"381","volume":"21","author":"G Papaxoinis","year":"2016","unstructured":"Papaxoinis G, Syrigos K, Saif MW (2016) New concepts in the treatment strategy of neuroendocrine tumors: the role of biotherapy. Discov Med 21(117):381\u2013389","journal-title":"Discov Med"},{"issue":"117","key":"3462_CR8","first-page":"391","volume":"21","author":"G Papaxoinis","year":"2016","unstructured":"Papaxoinis G, Syrigos K, Saif MW (2016) Novel therapeutic approaches and mechanisms in neuroendocrine tumors: the role of targeted agents. Discov Med 21(117):391\u2013402","journal-title":"Discov Med"},{"key":"3462_CR9","doi-asserted-by":"publisher","unstructured":"Khagi S, Saif MW (2014) Gastroenteropancreatic neuroendocrine tumors: hormonal treatment updates. JOP15(2):135\u2013137. doi: 10.6092\/1590-8577\/2287","DOI":"10.6092\/1590-8577\/2287"},{"key":"3462_CR10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000051862","volume":"62","author":"K Oberg","year":"2000","unstructured":"Oberg K (2000) Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 62:92","journal-title":"Digestion"},{"key":"3462_CR11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12672-015-0233-2","volume":"6","author":"HE Bainbridge","year":"2015","unstructured":"Bainbridge HE, Larbi E, Middleton G (2015) Symptomatic control of neuroendocrine tumours with everolimus. Horm Cancer 6:254\u2013259","journal-title":"Horm Cancer"},{"key":"3462_CR12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/annonc\/mdq670","volume":"22","author":"J Capdevila","year":"2011","unstructured":"Capdevila J, Miranda ID, Obiols G, Tabernero J (2011) Control of carcinoid syndrome with everolimus. Ann Oncol 22:237\u2013239","journal-title":"Ann Oncol"},{"key":"3462_CR13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4155\/cli.15.10","volume":"5","author":"P Lapuerta","year":"2015","unstructured":"Lapuerta P, Zambrowicz B, Fleming D, Wheeler D, Sands A (2015) Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome. Clin Investig 5:447 \u2013 56","journal-title":"Clin Investig"},{"key":"3462_CR14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/ERC-14-0173","volume":"21","author":"MH Kulke","year":"2014","unstructured":"Kulke MH, O\u2019Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC (2014) Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer 21:705\u2013714","journal-title":"Endocr Relat Cancer"},{"key":"3462_CR15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0016-5085(65)80089-0","volume":"48","author":"KL Melmon","year":"1965","unstructured":"Melmon KL, Sjoerdsma A, Oates JA, Laster L (1965) Treatment of malabsorption and diarrhea of the carcinoid syndrome with methysergide. Gastroenterology 48:13","journal-title":"Gastroenterology"},{"key":"3462_CR16","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJM196711232772101","volume":"277","author":"K Engelman","year":"1967","unstructured":"Engelman K, Lovenberg W, Sjoerdsma A (1967) Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome. N Engl J Med 277:1103\u20131108","journal-title":"N Engl J Med"},{"key":"3462_CR17","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1210\/jc.2014-2247","volume":"100","author":"M Pavel","year":"2015","unstructured":"Pavel M, H\u00f6rsch D, Caplin M, Ramage J, Seufferlein T, Valle J, Banks P, Lapuerta P, Sands A, Zambrowicz B (2015) Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab 100:1511\u20131519","journal-title":"J Clin Endocrinol Metab"},{"key":"3462_CR18","doi-asserted-by":"crossref","first-page":"422PD","DOI":"10.1093\/annonc\/mdw369.07","volume":"27","author":"M Kulke","year":"2016","unstructured":"Kulke M, H\u00f6rsch D, Caplin M, Anthony L, Bergsland E, Oberg K, Welin S, Warner R, Bohas CL, Kunz P (2016) Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome. Ann Oncol 27:422PD","journal-title":"Ann Oncol"},{"issue":"1","key":"3462_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/CCO","volume":"27","author":"S Khagi","year":"2015","unstructured":"Khagi S, Saif MW (2015) Pancreatic neuroendocrine tumors: targeting the molecular basis of disease. Curr Opin Oncol 27(1):38\u201343. doi: 10.1097\/CCO","journal-title":"Curr Opin Oncol"},{"key":"3462_CR20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2147\/OTT.S72155","volume":"9","author":"EA Kotteas","year":"2016","unstructured":"Kotteas EA, Syrigos KN, Saif MW (2016) Profile of capecitabine\/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors. Onco Targets Ther 9:699\u2013704. doi: 10.2147\/OTT.S72155","journal-title":"Onco Targets Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3462-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3462-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3462-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T17:29:59Z","timestamp":1570210199000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3462-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,19]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3462"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3462-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,19]]}}}